Baye Ashenef

Mr. Baye Ashenef

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2023 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
BABaye Ashenef
Baye Ashenef
MDMengistie Diress
Mengistie Diress
YYYigizie Yeshaw
Yigizie Yeshaw
BDBaye Dagnew
Baye Dagnew
YGYibeltal Yismaw Gela
Yibeltal Yismaw Gela
KAKassa Tesema Abebaw
Kassa Tesema Abebaw
Background: Visual impairment is one of the most common long-term effects of high blood pressure. It affects one’s quality of life, independence, and mobility. There is a paucity of information regarding the prevalence of visual impairment due to hypertension in Ethiopia. Therefore, this study aimed to determine the prevalence of visual impairment and its associated factors among hypertensive patients in referral hospitals of the Amhara region, Ethiopia, 2021. Methods: An institution-based cross-sectional study was conducted among 423 study participants, which were selected by systematic random sampling technique. Data were collected by using an interviewer-administered structured questionnaire and physical measurements. The collected data were entered into Epi-data version 4.6. Then, exported into SPSS Version 26 for analysis. The crude and adjusted odds ratios and 95% Confidence intervals were calculated. Both bivariable and multivariable logistic regression analyses were done. Variables with a p-value of ≤ 0.05 were stated as significantly associated with visual impairment. Results: The overall prevalence of visual impairment among hypertensive patients was 32.4% (95% CI: 27.9– 37.9). Duration of hypertension ≥ 5 years (AOR =3.06, 95% CI: 1.86– 4.95), history of ocular trauma (AOR =2.50, 95% CI: 1.3– 4.73), and ever alcohol drinking (AOR = 2.72, 95% CI: 1.32– 5.62) were significantly associated with visual impairment. Conclusion: Nearly one-third of hypertensive patients were visually impaired from the study participants. Duration of hypertension ≥ 5 years, history of ocular trauma, and ever alcohol drinking was significantly associated with visual impairment among hypertensive patients. Therefore, in addition to providing medical care and follow-up services for hypertension patients, health education is needed for early and proper management of visual impairment, and to decrease their level of alcohol consumption. Furthermore, better to do this study by prospective cohort study design to identify cause-and-effect relationships.

1 January 2025 in AIDS Research and Treatment
Verified
Journal Article
Open access
MJMohammed Jemal
Mohammed Jemal
AAAdane Adugna
Adane Adugna
MGmamaru engda getinet
mamaru engda getinet
BABaye Ashenef
Baye Ashenef
GBGelagey Baye
Gelagey Baye
EMEnyew Fenta Mengistu
Enyew Fenta Mengistu
Background: Dyslipidemia is a prevalent public health concern among individuals living with HIV who are undergoing antiretroviral therapy (ART), and it increases the risk of cardiovascular diseases. Despite the introduction of improved medications like dolutegravir, there are limited data regarding the extent of dyslipidemia in this population. Therefore, the purpose of this study was to determine the prevalence of dyslipidemia and its associated factors among people living with HIV on dolutegravir‐based ART. Methods: An institutional‐based cross‐sectional study was carried out from December 1, 2021, to February 30, 2022. Sociodemographic, behavioral, clinical, anthropometric, and laboratory data were collected from 423 participants. Simple random sampling methods were used to recruit the participants. The collected data were entered in Epi‐data Version 4.6 and analyzed via SPSS Version 26. Multivariable logistic regression was used to determine factors associated with dyslipidemia. A p value of < 0.05 was considered statistically significant. Results: The prevalence of dyslipidemia was found to be 73.8%. Low HDL‐C was the most common (61.2%), followed by elevated levels of TG (40.2%), high LDL‐C (26%), and high TC (24.3%). Being female (AOR = 1.77, 95% CI: 1.04–3.02, p = 0.034), insufficient physical activity (AOR = 1.64, 95% CI: 1–2.67, p = 0.048), being overweight (AOR = 2.25, 95% CI: 1.07–4.75, p = 0.033), and being obese (AOR = 2.32, 95% CI: 0.86–6.25, p = 0.045) were significantly associated with dyslipidemia. Conclusion: The prevalence of dyslipidemia among people living with HIV on a dolutegravir‐based ART was high, occurring in nearly three‐quarters of the participants. Being female, insufficient physical activity, and being overweight or obese were significantly associated with dyslipidemia among people living with HIV taking dolutegravir‐based ART. Therefore, to avoid the disastrous effects of dyslipidemia, serum lipid profiles should be considered and evaluated in people living with HIV on a dolutegravir‐based ART.

20 March 2025 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
BABaye Ashenef
Baye Ashenef
BYBayu Wondimneh Yimenu
Bayu Wondimneh Yimenu
EOEnatnesh Essa Osman
Enatnesh Essa Osman
DSDerese Sinamaw
Derese Sinamaw
GBGelagey Baye
Gelagey Baye
MJMohammed Jemal
Mohammed Jemal
Background: Excessive body weight are global health challenge affecting individuals across all age groups. They result from an imbalance between calorie intake and expenditure. Individuals with visual impairment are particularly vulnerable due to reduced physical activity, leading to higher rates of excessive body weight. This study assessed the prevalence and determinants of excessive body weight among visually impaired patients in northwest Ethiopia in 2024.Method: A multi-centered institution-based cross-sectional study was done with 384 visually impaired patients selected using a simple random sample technique. An interviewer-administered structured questionnaire and physical assessments were used to gather data. The crude and adjusted odds ratios, as well as the 95% confidence intervals, were calculated. Bivariate and multivariate logistic regression analyses were performed. Variables having a p-value < 0.05 were considered substantially associated with excessive body weight.Results: The prevalence of excessive body weight was 27.9% (95% CI: 23.2–32.8). Factors significantly associated with excessive body weight included being aged 65 or older (AOR = 5.43, 95% CI: 1.22–24.1), urban residency (AOR = 4.84, 95% CI: 2.95–7.95), and having visual impairment for five or more years (AOR = 3.33, 95% CI: 1.88–5.89).Conclusion: Excessive body weight affects nearly one-third of visually impaired patients in northwest Ethiopia, with significant associations found for older age, urban residence, and long-term visual impairment. Integrating weight management programs, physical activity promotion, nutritional education, and community support is essential to improve health outcomes. Future studies using prospective cohort designs are recommended to explore causal relationships.

7 November 2025 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
BABaye Ashenef
Baye Ashenef
BYBayu Wondmneh Yimenu
Bayu Wondmneh Yimenu
EOEnatnesh Essa Osman
Enatnesh Essa Osman
DSDerese Sinamaw
Derese Sinamaw
GBGelagey Baye
Gelagey Baye
MJMohammed Jemal
Mohammed Jemal
Hypertension frequently coexists with chronic conditions such as diabetes, dyslipidemia, chronic kidney disease, and obesity. This study aimed to assess the prevalence and associated factors of comorbidities among hypertensive patients in northwest Ethiopia. A multi-centered, institution-based cross-sectional study was conducted in 2024 among 423 randomly selected hypertensive patients. Data was collected through structured interviews and physical assessments. Bivariate and multivariate logistic regression analyses were employed to identify significant associations, with p-values < 0.05 considered statistically significant. The prevalence of comorbidities among hypertensive patients was 30.5% (95% CI: 26.2–34.8%). The most common comorbidities were chronic kidney disease (10.9%), diabetes mellitus (9%), dyslipidemia (7.5%), and obesity (3.1%). Factors significantly associated with comorbidity included age ≥ 65 years (AOR = 1.77), hypertension duration ≥ 5 years (AOR = 1.99), alcohol consumption (AOR = 1.93), and physical inactivity (AOR = 1.9). Nearly one-third of hypertensive patients had at least one comorbid condition. The findings underscore the importance of early detection, integrated care, and targeted interventions, which are supported by enhanced diagnostic services, health worker training, and public awareness. Further longitudinal and community-based studies are recommended to explore causality and broader impacts.

27 October 2026 in Cell Biology and Toxicology
Verified
Journal Article
Open access
PDF file
MTMelkamu Tilahun
Melkamu Tilahun
AAAdane Adugna
Adane Adugna
TBTemesgen Baylie
Temesgen Baylie
NYNibret Abebaw Yeneneh
Nibret Abebaw Yeneneh
MDMegbar Dessalegn
Megbar Dessalegn
MJMohammed Jemal
Mohammed Jemal
Fibrotic diseases are progressive disorders characterized by excessive extracellular matrix (ECM) accumulation, pathological tissue remodeling, progressive organ dysfunction, and increased mortality. Despite their substantial clinical burden, effective therapies capable of preventing, reversing or curing established fibrosis remain limited. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) has emerged as a potential molecular target in fibrotic diseases, although its contribution to fibrotic remodeling appears to vary across organs and disease contexts. This review summarizes current evidence on the involvement of LOX-1 in fibrotic remodeling across major organs, the potential utility of sLOX-1 as a component of multimarker panels for the detection and monitoring of fibrotic diseases, and emerging therapeutic strategies targeting LOX-1 in fibrosis. Experimental and clinical evidence suggests that LOX-1 is associated with fibrotic remodeling through its interconnected mechanisms involving oxidative stress, inflammation, endothelial and epithelial injury, fibroblast and myofibroblast activation, dysregulated TGF-β/SMAD and related signaling pathways, and altered ECM turnover. However, the strength and mechanistic specificity of evidence vary considerably among tissues, organs and disease models. Circulating soluble LOX-1 (sLOX-1) shows promise as a complementary biomarker alongside established markers in multimarker panels for assessing fibrosis, although its specificity and clinical utility for fibrosis remain uncertain. Several direct and indirect LOX-1-targeted therapeutic approaches are emerging; however, their antifibrotic efficacy, safety, and clinical applicability remain to be established. Overall, LOX-1 represents a promising but incompletely validated biomarker and therapeutic target in fibrotic diseases. Further cell and tissue-specific mechanistic studies, multi-omics and spatial investigations, biomarker validation, and well-designed clinical trials are needed to clarify its diagnostic, prognostic, and therapeutic utility and its potential role in individualized antifibrotic treatment.

1 January 2025 in Journal of Diabetes Research
Verified
Journal Article
Open access
DSDeresse Sinamaw
Deresse Sinamaw
TATadegew Adane
Tadegew Adane
BABaye Ashenef
Baye Ashenef
TBTemesgen Baylie
Temesgen Baylie
YSYeshimareg Shita
Yeshimareg Shita
Introduction: There is a notable link between diabetes mellitus (DM) and cardiovascular diseases (CVDs), particularly abnormal ventricular repolarization marked by a prolonged QT interval, which significantly contributes to morbidity and mortality in diabetic patients. However, no studies have been conducted in Ethiopia regarding prolonged QT intervals in Type 2 diabetic patients. Therefore, this study is aimed at examining the prevalence of prolonged QT intervals and the associated factors among Type 2 diabetic patients in selected referral hospitals in the Amhara Region, Ethiopia. Methods: A cross‐sectional study was conducted from May 30, 2024, to September 30, 2024, involving 300 participants. Participants were selected using systematic sampling. Data were collected through questionnaires, anthropometric measurements, blood pressure readings, and lipid profile analyses. QTc interval was determined by using digital electrocardiographic machine. The study utilized bivariable and multivariable logistic regression models to identify factors associated with prolonged QT intervals. Results: The average QT interval was 420 ± 4.8 ms, with 45.6% of patients exhibiting prolonged QT intervals. Multivariable logistic regression analysis identified significant associations between prolonged QT intervals and factors such as age (AOR 1.11, 95% CI: 1.01–2.42), duration of diabetes (AOR 2.52, 95% CI: 1.12–5.31), body mass index (AOR 1.65, 95% CI: 1.21–3.44), fasting blood sugar (AOR 2.21, 95% CI: 1.12–6.21), sulfonylureas drug treatment (AOR 2.42, 95% CI: 1.21–5.94), HbA1c (AOR 2.78, 95% CI: 1.07–6.48), and total cholesterol (AOR 6.21, 95% CI: 4.25–11.25). Conclusion: This study highlights the significant prevalence of prolonged QT intervals among Type 2 diabetic patients. Several factors significantly contribute to the likelihood of prolonged QT intervals in Type 2 diabetic patients. These include older age, longer duration of diabetes, higher BMI, elevated fasting blood sugar levels, use of sulfonylureas, higher HbA1c levels, and elevated total cholesterol. This significant finding underscores the importance of regular cardiovascular monitoring and effective management strategies to mitigate the risks associated with prolonged QT intervals in this population.